Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases

doi:10.3748/wjg.v20.i15.4263

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 15

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6872)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

544

WORD

183

HTML

4074

Tables (1-1)

184

Sum=4985

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1019

Download

868

Sum=1887

Apr 21, 2014 (publication date) through Nov 2, 2024

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 21, 2014; 20(15): 4263-4275
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4263

Table 1 Phase II/III clinical trials of targeted agents in combination with chemotherapy as first-line treatments for metastatic colorectal cancer

Clinical trial(reporters)	Year	Primary end point	Population	Regimen	Patient number	Median PFS(mo)	HRP value (95%CI)	Median OS(mo)	HRP value (95%CI)	Response rates	ORP value (95%CI)
CRYSTAL[26]	2009	PFS	ITT	FOLFIRI + Cet	599	8.9	HR = 0.85 ^aP = 0.048	19.9	HR = 0.93 P = 0.31	46.90%	OR = 1.403 ^aP = 0.0038
			ITT	FOLFIRI	599	8.0	HR = 0.85 ^aP = 0.048	18.6	HR = 0.93 P = 0.31	38.70%	OR = 1.403 ^aP = 0.0038
			KRAS WT subgroup	FOLFIRI + Cet	316	9.9	HR = 0.696 ^aP = 0.0012	23.5	HR = 0.796 ^aP = 0.0093	57.30%	OR = 2.069 ^aP < 0.001
			KRAS WT subgroup	FOLFIRI	350	8.4	HR = 0.696 ^aP = 0.0012	20	HR = 0.796 ^aP = 0.0093	39.70%	OR = 2.069 ^aP < 0.001
			KRAS MT subgroup	FOLFIRI + Cet	214	7.4	HR = 1.171 P = 0.26	16.2	HR = 1.035 P = 0.75	31.30%	OR = 0.822 P = 0.35
			KRAS MT subgroup	FOLFIRI	183	7.7	HR = 1.171 P = 0.26	16.7	HR = 1.035 P = 0.75	36.10%	OR = 0.822 P = 0.35
OPUS[27]	2009	Response rates	ITT	FOLFOX4 + Cet	169	7.2	HR = 0.931 P = 0.62	18.3	HR = 1.015 P = 0.91	46%	OR = 1.516 P = 0.064
			ITT	FOLFOX4	168	7.2	HR = 0.931 P = 0.62	18.0	HR = 1.015 P = 0.91	36%	OR = 1.516 P = 0.064
			KRAS WT subgroup	FOLFOX4 + Cet	82	8.3	HR = 0.567 ^aP = 0.0064	22.8	HR = 0.855 P = 0.39	57%	OR = 2.551 ^aP = 0.0027
			KRAS WT subgroup	FOLFOX4	97	7.2	HR = 0.567 ^aP = 0.0064	18.5	HR = 0.855 P = 0.39	34%	OR = 2.551 ^aP = 0.0027
			KRAS MT subgroup	FOLFOX4 + Cet	77	5.5	HR = 1.72 ^aP = 0.0153	13.4	HR = 1.290 P = 0.20	34%	OR = 0.459 ^aP = 0.029
			KRAS MT subgroup	FOLFOX4	59	8.6	HR = 1.72 ^aP = 0.0153	17.5	HR = 1.290 P = 0.20	53%	OR = 0.459 ^aP = 0.029
COIN[24]	2011	OS	KRAS WT	FOLFOX/XELOX + Cet	362	8.6	HR = 0.96 P = 0.60	17.0	HR = 1.04 P = 0.68	64%	OR = 1.35 ^aP = 0.049
			KRAS WT	FOLFOX/XELOX	367	8.6	HR = 0.96 P = 0.60	17.9	HR = 1.04 P = 0.68	57%	OR = 1.35 ^aP = 0.049
			KRAS WT	FOLFOX + Cet	117	9.0	HR = 0.77 P = 0.056	-	-	-	-
			KRAS WT	FOLFOX	127	9.2	HR = 0.77 P = 0.056	-	-	-	-
			KRAS WT	XELOX + Cet	245	8.4	HR = 1.06 P = 0.56	-	-	-	-
			KRAS WT	XELOX	240	8.0	HR = 1.06 P = 0.56	-	-	-	-
			KRAS MT	FOLFOX/XELOX + Cet	297	-	-	13.6	HR = 0.98 P = 0.80	-	-
			KRAS MT	FOLFOX/XELOX	268	-	-	14.8	HR = 0.98 P = 0.80	-	-
NORDIC-VII[29]	2012	PFS	ITT	FLOX + Cet	194	8.3	HR = 0.89 P = 0.31	19.7	HR = 1.06 P = 0.67	49%	OR = 1.35 P = 0.15
				Intermittent FLOX + Cet	187	7.3	Not reported	20.3	HR = 1.03 P = 0.79	47%	Not report
				Nordic FLOX	185	7.9	Control	20.4	Control	41%	Control
			KRAS WT subgroup	FLOX + Cet	97	7.9	HR = 1.07 P = 0.66	20.1	HR = 1.14 P = 0.48	46%	OR = 0.96 P = 0.89
				Intermittent FLOX + Cet	109	7.5	Not reported	21.4	HR = 1.08 P = 0.66	51%	OR = 0.96 P = 0.89
				Nordic FLOX	97	8.7	Control	22.0	Control	47%	Control
			KRAS MT subgroup	FLOX + Cet	72	9.2	HR = 0.71 P = 0.07	21.1	HR = 1.03 P = 0.89	49%	OR = 1.44 P = 0.31
				Intermittent FLOX + Cet	65	7.2	Not reported	20.5	HR = 1.04 P = 0.84	42%	Not report
				Nordic FLOX	58	7.8	Control	20.4	Control	40%	Control
PRIME[30]	2010	PFS	KRAS WT	FOLFOX4 + Pan	325	9.6	HR = 0.80 ^aP = 0.02	23.9	HR = 0.83 P = 0.072	55%	OR = 1.35 P = 0.068
			KRAS WT	FOLFOX4	331	8.0	HR = 0.80 ^aP = 0.02	19.7	HR = 0.83 P = 0.072	48%	OR = 1.35 P = 0.068
			KRAS MT	FOLFOX4 + Pan	221	7.3	HR = 1.29 ^aP = 0.02	15.5	HR = 1.24 P = 0.068	40%	-
			KRAS MT	FOLFOX4	219	8.8	HR = 1.29 ^aP = 0.02	19.3	HR = 1.24 P = 0.068	40%	-
AVF2107g[32]	2004	OS	ITT	IFL + Bev	402	10.6	HR = 0.54 ^aP < 0.001	20.3	HR = 0.66 ^aP < 0001	44.80%	^aP = 0.004
AVF2107g[32]	2004	OS	ITT	IFL	411	6.2	HR = 0.54 ^aP < 0.001	15.6	HR = 0.66 ^aP < 0001	34.80%	^aP = 0.004
NO16966[33]	2008	PFS	ITT	FOLFOX4/XELOX + Bev	699	9.4	HR = 0.83 ^aP = 0.0023	21.3	HR = 0.89 P = 0.0769	38%	OR = 1.00 P = 0.99
			ITT	FOLFOX4/XELOX	701	8.0	HR = 0.83 ^aP = 0.0023	19.9	HR = 0.89 P = 0.0769	38%	OR = 1.00 P = 0.99
			Subgroup	FOLFOX4 + Bev	349	9.4	HR = 0.89 97.5%CI: 0.73-1.08	21.2	HR = 0.94 97.5%CI: 0.75-1.16	-	-
			Subgroup	FOLFOX4	351	8.6	HR = 0.89 97.5%CI: 0.73-1.08	20.3	HR = 0.94 97.5%CI: 0.75-1.16	-	-
			Subgroup	XELOX + Bev	350	9.3	HR = 0.77 97.5%CI: 0.63-0.94	21.4	HR = 0.84 97.5%CI: 0.68-1.04	-	-
			Subgroup	XELOX	350	7.4	HR = 0.77 97.5%CI: 0.63-0.94	19.2	HR = 0.84 97.5%CI: 0.68-1.04	-	-
CAIRO-2[67]	2009	PFS	ITT	XELOX + Bev + Cet	368	9.4	HR = 1.22 ^aP = 0.01	19.4	HR = 1.15 P = 0.16	52.70%	P = 0.49
			ITT	XELOX + Bev	368	10.7	HR = 1.22 ^aP = 0.01	20.3	HR = 1.15 P = 0.16	50%	P = 0.49
			KRAS WT subgroup	XELOX + Bev + Cet	158	10.5	P = 0.30	21.8	P = 0.64	61.40%	P = 0.06
			KRAS WT subgroup	XELOX + Bev	156	10.6	P = 0.30	22.4	P = 0.64	50.00%	P = 0.06
			KRAS MT subgroup	XELOX + Bev + Cet	98	8.1	^aP = 0.003	17.2	^aP = 0.03	45.90%	^aP = 0.03
			KRAS MT subgroup	XELOX + Bev	108	12.5	^aP = 0.003	24.9	^aP = 0.03	59.20%	^aP = 0.03
PACCE[68]	2009	PFS	ITT	Ox-CT + Bev + Pan	413	10.0	HR = 1.27 95%CI: 1.06-1.52	19.4	HR = 1.43 95%CI: 1.11-1.83	46%	OR = 0.92 95%CI: 0.70-1.22
			ITT	Ox-CT + Bev	410	11.4	HR = 1.27 95%CI: 1.06-1.52	24.5	HR = 1.43 95%CI: 1.11-1.83	48%	OR = 0.92 95%CI: 0.70-1.22
			KRAS WT subgroup	Ox-CT + Bev + Pan	201	9.8	HR = 1.36 95%CI: 1.04-1.77	20.7	HR = 1.89 95%CI: 1.30-2.75 ^aP = 0.045	50%	-
			KRAS WT subgroup	Ox-CT + Bev	203	11.5	HR = 1.36 95%CI: 1.04-1.77	24.5	HR = 1.89 95%CI: 1.30-2.75 ^aP = 0.045	56%	-
			KRAS MT subgroup	Ox-CT + Bev + Pan	135	10.4	HR = 1.25 95%CI: 0.91-1.71	19.3	HR = 1.02 95%CI: 0.67-1.54	47%	-
			KRAS MT subgroup	Ox-CT + Bev	125	11.0	HR = 1.25 95%CI: 0.91-1.71	19.3	HR = 1.02 95%CI: 0.67-1.54	44%	-
			ITT	Iri-CT + Bev + Pan	115	10.1	HR = 1.19 95%CI: 0.79-1.79	20.7	HR = 1.42 95%CI: 0.77-2.62	43%	OR = 1.11 95%CI: 0.65- 1.90
			ITT	Iri-CT + Bev	115	11.7	HR = 1.19 95%CI: 0.79-1.79	20.5	HR = 1.42 95%CI: 0.77-2.62	40%	OR = 1.11 95%CI: 0.65- 1.90
			KRAS WT subgroup	Iri-CT + Bev + Pan	57	10.0	HR = 1.50 95%CI: 0.82-2.76	NE	HR = 1.28 95%CI: 0.50-3.25 P = 0.445	54%	-
				Iri-CT + Bev	58	12.5		19.8		48%
				Iri-CT + Bev	58	12.5		19.8		KRAS MT subgroup		Iri-CT + Bev + Pan	47	8.3	HR = 1.19 95%CI: 0.65-2.21	17.8	HR = 2.14 95%CI: 0.82-5.59	30%	-
			Iri-CT + Bev	39	11.9	20.5	38%			KRAS MT subgroup					HR = 1.19 95%CI: 0.65-2.21		HR = 2.14 95%CI: 0.82-5.59		-

^aP < 0.05. PFS: Progress-free survival; OS: Overall survival; ITT: Intent to treat; WT: Wild type; MT: Mutant type; NE: Not estimatable; KRAS: KRAS exon 2, codons 12 and 13; FOLFOX: Fluorouracil, leucovorin, and oxaliplatin; XELOX: Capecitabine and oxaliplatin; FLOX: Fluorouracil, leucovorin, and oxaliplatin; Ox-CT: Oxaliplatin-based chemotherapy; FOLFIRI: Irinotecan, fluorouracil, and leucovorin; IFL: Irinotecan, fluorouracil, and leucovorin; Iri-CT: Irinotecan-based chemotherapy; Cet: Cetuximab; Pan: Panitumumab; Bev: Bevacizumab.

Citation: Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014; 20(15): 4263-4275
URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4263.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i15.4263